Chargement en cours...
Novel therapies in thrombotic thrombocytopenic purpura
ESSENTIALS: The standard of care for patients with TTP remains daily plasma exchange in addition to immune suppressive therapy. Despite the improved treatment options for TTP, the acute mortality of TTP remains between 15‐20%. Caplacizumab reduces the time to platelet recovery and the exacerbation r...
Enregistré dans:
| Publié dans: | Res Pract Thromb Haemost |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6055500/ https://ncbi.nlm.nih.gov/pubmed/30046703 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rth2.12066 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|